PGR logo Progressive Corporation +
Progressive Corporation
+

Progressive Corporation (PGR) Business News

Track Progressive Corporation in real time with a live news feed covering Progressive Corporation stock news, official press releases, company announcements, and an archive of historical Progressive Corporation news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
8:16 AM | Wednesday | Oct 14, 2026 GlobeNewsWire

Progressive Reports September 2026 Results

News Thumbnail
9:00 AM | Monday | Oct 12, 2026 Business Wire

Corebridge Financial Introduces Progressive Trigger, a First-of-Its-Kind Index Annuity Strategy Designed to Turn Missed Years into Future Opportunity

News Thumbnail
8:00 AM | Wednesday | Oct 7, 2026 GlobeNewsWire

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

News Thumbnail
7:05 AM | Wednesday | Oct 7, 2026 GlobeNewsWire

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

News Thumbnail
8:17 AM | Friday | Sep 18, 2026 GlobeNewsWire

Progressive Reports August 2026 Results

News Thumbnail
2:00 AM | Wednesday | Sep 16, 2026 GlobeNewsWire

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease

News Thumbnail
12:00 AM | Thursday | Sep 3, 2026 GlobeNewsWire

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China

News Thumbnail
8:16 AM | Wednesday | Aug 19, 2026 GlobeNewsWire

Progressive Reports July 2026 Results

News Thumbnail
7:00 AM | Monday | Aug 17, 2026 Business Wire

United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

News Thumbnail
8:37 AM | Friday | Jul 24, 2026 GlobeNewsWire

Progressive Announces Investor Relations Event

News Thumbnail

Progressive Reports September 2026 Results

GlobeNewsWire

8:16 AM | Wednesday | Oct 14, 2026

news photo
Loading...

MAYFIELD VILLAGE, OHIO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Progressive Corporation (NYSE:PGR) today reported the following results for the month and quarter ended September 30, 2026:

Read full article redirect
8:16 AM | Wednesday | Oct 14, 2026

Progressive Reports September 2026 Results

GlobeNewsWire

MAYFIELD VILLAGE, OHIO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Progressive Corporation (NYSE:PGR) today reported the following results for the month and quarter ended September 30, 2026:

Read full article arrow
News Thumbnail
9:00 AM | Monday | Oct 12, 2026

Corebridge Financial Introduces Progressive Trigger, a First-of-Its-Kind Index Annuity Strategy Designed to Turn Missed Years into Future Opportunity

Business Wire

HOUSTON--(BUSINESS WIRE)--Corebridge Financial today announced the launch of Progressive Trigger, a first-of-its-kind index annuity interest-crediting strategy designed to help customers preserve future growth potential despite a down year. Many retirement savers understand that markets do not move in a straight line and that recoveries often take time. Progressive Trigger's built-in Memory feature is designed for this possibility, allowing eligible interest percentages to accumulate following.

Read full article arrow
News Thumbnail
8:00 AM | Wednesday | Oct 7, 2026

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

GlobeNewsWire

Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS  Updated Phase 1 investigator-initiated trial data to be presented, continuing to highlight encouraging clinical activity and a well-tolerated safety profile in progressive multiple sclerosis EMERYVILLE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced two abstracts selected for presentation at the MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting, taking place from October 21-23, 2026, in Toronto, Canada.

Read full article arrow
News Thumbnail
7:05 AM | Wednesday | Oct 7, 2026

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

GlobeNewsWire

WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced that it will present seven posters at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026) taking place October 21-23, 2026, in Toronto, Canada.

Read full article arrow
News Thumbnail
8:17 AM | Friday | Sep 18, 2026

Progressive Reports August 2026 Results

GlobeNewsWire

MAYFIELD VILLAGE, OHIO, Sept. 18, 2026 (GLOBE NEWSWIRE) -- The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended August 31, 2026:

Read full article arrow
News Thumbnail
2:00 AM | Wednesday | Sep 16, 2026

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease

GlobeNewsWire

The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease

Read full article arrow
News Thumbnail
12:00 AM | Thursday | Sep 3, 2026

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China

GlobeNewsWire

The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease

Read full article arrow
News Thumbnail
8:16 AM | Wednesday | Aug 19, 2026

Progressive Reports July 2026 Results

GlobeNewsWire

MAYFIELD VILLAGE, OHIO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended July 31, 2026:

Read full article arrow
News Thumbnail
7:00 AM | Monday | Aug 17, 2026

United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

Business Wire

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its TETON-PPF study evaluating the use of Tyvaso® (treprostinil) inhalation solution (nebulized Tyvaso) for the treatment of progressive pulmonary fibrosis (PPF). The TETON-PPF study enrolled 754 patients.
“The rapid pace of enrollment underscores both the significant unmet need for new treatment options in PPF and the strong interest in nebulized Tyvas.

Read full article arrow
News Thumbnail
8:37 AM | Friday | Jul 24, 2026

Progressive Announces Investor Relations Event

GlobeNewsWire

MAYFIELD VILLAGE, OHIO, July 24, 2026 (GLOBE NEWSWIRE) -- As previously announced, The Progressive Corporation (NYSE: PGR) will host an Investor Relations event on Tuesday, August 4, 2026, beginning at 9:30 a.m. eastern time. This event, which will consist of both a conference call and webcast, is scheduled to last 90 minutes and will begin with an approximately 45-minute presentation on our Robinsons consumer segment, followed by a question-and-answer session with Tricia Griffith, our CEO, and Andrew Quigg, our CFO. Call-in participants will be able to ask questions via phone, however, webcast participants will not be able to submit questions online.

Read full article arrow
News Thumbnail